Actively Recruiting
Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
Led by Tanta University · Updated on 2026-04-15
46
Participants Needed
1
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
CONDITIONS
Official Title
Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with active rheumatoid arthritis (not in remission) defined by a 28-joint disease activity score (DAS28) above 2.6
- Patients receiving conventional disease-modifying antirheumatic drugs (DMARDs)
- Adults aged 18 to 70 years
You will not qualify if you...
- Patients with heart disease including congestive heart failure, arrhythmia, or ischemic heart disease
- Patients with diabetes or active infections
- Patients with severe kidney or liver problems
- Patients receiving biological DMARDs
- Patients taking oral prednisolone over 15 mg per day
- Patients allergic to the study medication
- Patients using antioxidants
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta university
Tanta, Gharbia Governorate, Egypt
Actively Recruiting
Research Team
K
Karim Abu Elfath Hussein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here